NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) has achieved a significant milestone by winning first place in the Healthcare category at the BOLD Awards VII Gala, held on March 27, 2026, in Barcelona. The award recognizes the company's leadership in developing exosome-based therapies for central nervous system (CNS) injuries, a field that holds promise for treating conditions such as acute spinal cord and optic nerve injuries. The BOLD Awards, which honor innovation and excellence across various industries, selected NurExone from a panel of global industry leaders, underscoring the potential impact of its technology.
The company also provided a corporate update, revealing plans to engage Investor Brand Network (IBN), subject to approval from the TSX Venture Exchange. The engagement, set to begin April 1, 2026, will focus on bolstering investor awareness efforts. Under a one-year agreement with a monthly fee of $6,500, IBN will distribute news and updates across more than 5,000 outlets, aiming to strengthen market visibility and enhance long-term shareholder value. This strategic move comes as NurExone advances its lead product, ExoPTEN, which has shown strong preclinical data and received Orphan Drug Designation, facilitating a regulatory roadmap toward clinical trials in the United States and Europe.
The implications of this announcement are multifaceted. Firstly, the BOLD Award win validates NurExone's scientific approach and positions it as a key player in the regenerative medicine space, particularly for CNS injuries where treatment options are limited. The award could attract further attention from potential partners, investors, and the broader medical community. Secondly, the engagement of IBN for investor outreach signals a proactive effort to increase the company's profile among retail and institutional investors. With access to a vast network of wire solutions and editorial syndication, IBN can amplify NurExone's message, potentially driving greater interest and investment.
NurExone's focus on exosome-based therapies is particularly noteworthy. Exosomes are nano-sized vesicles that facilitate cell-to-cell communication, and harnessing them for targeted drug delivery offers a minimally invasive approach. The company's Exo-Top subsidiary, established in the U.S., anchors its North American activities and growth strategy. As NurExone progresses toward clinical trials, the success of its therapies could revolutionize treatment for spinal cord injuries, which affect thousands annually and often result in permanent disability. The Orphan Drug Designation not only provides regulatory benefits but also highlights the unmet medical need.
Overall, this announcement underscores NurExone's momentum in translating preclinical success into clinical and commercial realities. The combination of industry recognition and enhanced investor communication positions the company to capitalize on its advancements. For more details, the full press release is available at https://ibn.fm/cWtqT. Additional information about NurExone can be found at https://nurexone.com/.
